PRESS RELEASE published on 01/17/2024 at 15:00, 10 months 3 days ago Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform Xenetic Biosciences, Inc. has entered into a Research Funding Agreement and a Material Transfer Agreement with the University of Virginia to advance the development of its systemic DNase program, targeting neutrophil extracellular traps involved in cancer progression. The company believes that the data generated by its research and development collaborations are crucial for unlocking the potential of its DNase technology and driving a clinical path for its lead solid tumor indications. The agreement with UVA provides a significant addition to Xenetic's development capabilities and resources, accelerating development timelines. Dr. Allan Tsung, an internationally recognized surgical oncologist and scientist, will oversee the research conducted under the agreement. Xenetic is working towards its planned first-in-human study to evaluate DNase combined with immune checkpoint inhibitors or chemotherapy. For more information, visit Xenetic Biosciences' website at www.xeneticbio.com. Xenetic Biosciences DNase Program Neutrophil Extracellular Traps Cancer Progression University Of Virginia
PRESS RELEASE published on 11/10/2023 at 14:35, 1 year ago Xenetic Biosciences, Inc. Reports Third Quarter 2023 Financial Results
PRESS RELEASE published on 10/11/2023 at 15:05, 1 year 1 month ago Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference
Published on 11/21/2024 at 14:15, 21 minutes ago neurocare Group AG Welcomes Kevin Reeder as Chief Financial Officer
Published on 11/21/2024 at 14:00, 36 minutes ago Demotech, Inc. Assigns a Financial Stability Rating(R) of A, Exceptional, to Steadily Insurance Company
Published on 11/21/2024 at 14:00, 36 minutes ago Montara Raises $5.4M to Help Organizations Deliver Better Data Products Faster
Published on 11/21/2024 at 14:00, 36 minutes ago Tevir Capital LP Ltd. Updates Early Warning Reporting in Respect of VerticalScope Holdings Inc.
Published on 11/21/2024 at 14:16, 20 minutes ago EQS-Adhoc: LM PAY S.A. Announces Third Quarter 2024 Preliminary Results and Updated Guidance
Published on 11/21/2024 at 14:15, 21 minutes ago ZenaTech Signs Blue UAS and NDAA Compliant Supply Chain Partners to Sell to US Defense Branches and NATO Forces
Published on 11/21/2024 at 12:35, 2 hours 1 minute ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 06:58, 7 hours 38 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 19 hours 16 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 51 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 51 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
